EFECTOS ADVERSOS DE LA VACUNACIÓN A PERSONAS CON VIH/SIDA

Alba María Vega Viyuela

Resumen


Antecedentes: Las personas portadoras del Virus de Inmunodeficiencia Adquirida (VIH) representa un grupo de especial atención para su cuidado, dadas las condiciones de presentar un sistema inmunitario comprometido. Estas personas tienen mayor riesgo de sufrir infecciones y de sufrir efectos adversos derivados de la vacunación, por lo tanto, resulta de interés un estudio detallado de su vacunación. Metodología: Estudio descriptivo mediante una búsqueda bibliográfica. Resultados: 50 artículos que permiten una descripción detallada de las características de un conjunto de 14 vacunas para este grupo de personas. Conclusiones: La mayoría de las vacunas valoradas se recomiendan. La situación ideal es un recuento de CD4 sea >200 células/mm3 y con tratamiento antirretroviral.

Palabras clave


vacuna; vacunoterapia; prevención primaria; efectos adversos; VIH; SIDA;

Citas


Ward, BJ (2000): “Vaccine adverse events in the new millennium: in there reason for concern?”, nº 78 (2), boletín WHO, página 11.

Ministerio de Salud Pública español (2004) “Vacunas recomendadas en personas infectadas por el virus de la inmunodeficiencia humana” Capítulo 4. Vacunación en Adultos. Recomendaciones 2004, , España, páginas 71-73.

Hussay G. et al. (2004). Adverse Effects of Bacille Calmette-Guérin Vaccination in HIV-Positive Infants. Oxford Journals. Clinical Infectious Diseases, nº 38 (9), páginas 1334-1333. Consulta 3 enero, 2015, de la Wold Wide Web: http://cid.oxfordjournals.org/content/38/9/1333.extract?sid=43d73418-ff44-4fc1-a821-90a2d9871928

Puthanakit t. Et al. (2005). Immune Reconstitution Syndrome Due to Bacillus Calmette-Guérin after Initiation of Antiretroviral Therapy in Children with HIV Infection. Clinical Infectious Diseases, nº 41 (7), páginas 1052-1049. Consulta 3 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924528/

Waddel RD. Et al. (2000). Safety and Immunogenicity of a Five-Dose Series of Inactivated Mycobacterium vaccae Vaccination for the Prevention of HIV-Associated Tuberculosis. Oxford Journals. Clinical Infectious Diseases, nº 30 (3), páginas 5315-5309. Consulta 3 enero, 2015, de la Wold Wide Web: http://cid.oxfordjournals.org/content/30/Supplement_3/S309.full

Juzi JT., Sidler D., Moore SW. (2008). Surgical management of BCG vaccineinduced regional axillary lymphadenitis in HIV-infected children. South African Medical Journal. nº 46 (2), páginas 55-52. Consulta 3 enero, 2015, de la Wold Wide Web: http://www.ajol.info/index.php/sajs/article/view/34405

Bannister C., Bennett L., Carville A., Azzopardi P. (2009). Evidence behind the WHO Guidelines: Hospital Care for Children: What is the Evidence that BCG Vaccination Should Not be Used in HIV-infected Children?. Oxford Journals. Journal of Tropical Pediatrics nº 55 (2), páginas 82-78. Consulta 3 enero, 2015, de la Wold Wide Web: http://tropej.oxfordjournals.org/content/55/2/78.full

Fordham von Reyn C. (2005). Routine Childhood Bacille Calmette Guerin Immunization and HIV Infection. Clinical Infectious Diseases, 2006, nº 42, páginas 559–6. Consulta 3 enero, 2015, de la Wold Wide Web: http://cid.oxfordjournals.org/

Hesseling AC. Et al. (2003). Danis Bacille Calmette-Gue´rin Vaccine–Induced Disease in Human Immunodeficiency Virus–Infected Children. Oxford Journals, Clinical Infecttious Diseases, nº 37 (9), páginas 1233-1226. Consulta 3 enero, 2015, de la Wold Wide Web: http://cid.oxfordjournals.org/content/37/9/1226.abstract?sid=c3d093fb-7f8f-4075-bfa3-7592fa4a4f84

Karpelowsky JS., Alexsander AG, Peek SD., Millar AJ., Rode H. (2008) Surgical complications of bacille Calmette-Guérin (BCG) infection in HIV-infected children: time for a change in policy?. South African Medical Journal, nº 93 (10), páginas 801-4. Consulta 3 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pubmed/19115758

Nuttal JJ., Davies MA., Hussey GD., Eley BS. (2008). Bacillus Calmette–Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. International Journal of Infectious Diseases, nº 12 (6), páginas 105-99. Consulta 3 enero, 2015, de la Wold Wide Web: http://www.ijidonline.com/article/S1201-9712(08)01413-6/abstract

Scriba TJ. et al. (2012). A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis –infected Adults. ATS Journals. ´nº 185 (7), páginas 778-769. Consulta 3 enero, 2015, de la Wold Wide Web: http://www.atsjournals.org/doi/abs/10.1164/rccm.201108-1548OC#.VmhAe89dG58

Puthanakit T, Aurpibul L, Yoksan S, Sirisanthana T, Sirisanthana V (2007): “Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antirretroviral therapy”, ELSEVIER, vacinne nº 25 (2007), páginas 8257-8261.

Veit O. et al. (2009). Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV-Infected Patients. Clinical Infectious Diseases, nº 48 (5), páginas 659-666. Consulta 3 enero, 2015, de la Wold Wide Web: m.cid.oxfordjournals.org/content/48/5/659.full

Thomas RE., Lorenzetti DL., Spragins W., Jackson D., Williamson T. (2012). The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic Review. The American Journal of Tropical Medicine and Hygiene, nº 86(2), páginas 359-372. Consulta 3 enero, 2015, de la Wold Wide Web: www.ncbi.nlm.nih.gov/pmc/articles/PMC3269291/#!po=1.07143

Barte H., Horvath TH., Rutherford GW. (2014). Yellow fever vaccine for patients with HIV infection (Review). The Chrocane Collaboration, Issue 1. Consulta 3 enero, 2015, de la Wold Wide Web: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010929.pub2/abstract

Weinberg A et al. (2005). Antibody Responses to Hepatitis A Virus Vaccine in HIV-Infected Children with Evidence of Immunologic Reconstitution while Receiving Highly Active Antiretroviral Therapy. The Journal of Infectious Diseases, nº 196, páginas 302-311. Consulta 3 enero, 2015, de la Wold Wide Web: m.jid.oxfordjournals.org/content/193/2/302.long

Wallace MR. et al. (2004). Safety and Immunogenicity of an Inactivated Hepatitis A Vaccine among HIV-Infected Subjects. Clinical Infectous Diseases, 2004, nº 39, páginas 1207–1213. Consulta 3 enero, 2015, de la Wold Wide Web: cid.oxfordjournals.org/content/39/8/1207.full

Kemper CA. (2003). Safety and Immunogenicity of Hepatitis A Vaccine in Human Immunodeficiency Virus–Infected Patients: A Double-Blind, Randomized, Placebo-Controlled Trial. The Journal of Infectious Diseases, 2003, nº 187, páginas 1327–31. Consulta 6 enero, 2015, de la Wold Wide Web: jid.oxfordjournals.org/content/187/8/1327.full

From carácter to personality: Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects. Clinical Trials, (2011): US. Consulta 10 enero, 2015, de la Wold Wide Web: http://clinicaltrials.gov/ct2/show/NCT01​289106

Overton ET. et al. (2010). Immune Response to Hepatitis B Vaccine in HIV-Infected Subjects Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as a Vaccine Adjuvant: ACTG Study 5220. NIH, Vaccine. 2010; nº 28(34), páginas 5597–5604. Consulta 6 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943846/

(2004): “Division of AIDS table for grading the severity os adults and pediatric adverse events version 1.0.”, Clarification, august 2009, página 21.

Ansaldi F. et a l. (2012). Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine vs. standard-dose intramuscular vaccine in HIV-1-infected adults. Hum Vaccin Immunother. 2012 nº 8(8), páginas: 1048-52. Consulta 6 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pubmed/22832261

Cooper C. Et al.(2012) High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. Pub Med. HIV Clin Trials. Nº 13(1), páginas 32-23. Consulta 6 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pubmed/22306585

Crum-Cianflon NF. Et al.(2011) Immunogenicity of a Monovalent 2009 Influenza A (H1N1) Vaccine in an Immunocompromised Population: A Prospective Study Comparing HIV-Infected Adults with HIV-Uninfected Adults. Clinical Infectious Diseases, nº 52 (1), páginas 138-46. Consulta 6 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pubmed/21148532

Noah McKittrick, MD. et al. (2013). Improved Immunogenicity With High-Dose Seasonal Influenza Vaccine in HIV-Infected Persons. Annals of International Medicine. nº158 (1), páginas 26-19. Consulta 6 enero, 2015, de la Wold Wide Web: http://annals.org/ on 12/08/2014

Steffens B. Et al. (2011). Acceptance And tolerability of An Adjuvanted nH1n1 vaccine in HIV-Infected patients In the cologne-Bonn cohort. European Journal of Medical Research, nº16, páginas 294-289. Consulta 6 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pubmed/21813369

Leahy TR., Goode M, Lynam P., Gavin PJ., Butler KM. (2014) HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children. Pub Med. Influenza Other Respir Viruses.. nº 8 (3), páginas 360-3. Consulta 6 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pubmed/24548473

Phongsamarta W. (2011) Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children. ELSEVIER. Vaccine nº 29, páginas 8711-8705. Consulta 6 enero, 2015, de la Wold Wide Web: www.elsevier.com/locate/vaccine

Beck CR., McKenzie BC., Hashim AB., Harris RC. (2012). Influenza Vaccination for Immunocompromised Patients: Systematic Review and Meta-analysis by Etiology. Oxford Journals. The journal os Unfectious Diseases 2012. Consulta 6 enero, 2015, de la Wold Wide Web: http://jid.oxfordjournals.org/content/early/2012/08/23/infdis.jis487.full

Ceravolo A., Orsi a., Parodi V., Rosselli R., Ansaldi F. (2013). Influenza vaccination in HIV-positive subjects: latest evidence and future perspective. Journal of Preventive Medicine and Hygiene. 2013 nº54 (1), páginas 10-1. Consulta 6 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pubmed/24396998

Vigano A. Et al.(2011) Long-Term Immunogenicity after One and Two Doses of a Monovalent MF59-Adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered with the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-Infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial. Clinical Vaccine Immunology. 2011 nº 9, páginas 1503-9. Consulta 6 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pubmed/21795458 GENBERAL

El Sahly Hana M., et al. (2012). Higher Antigen Content Improves the Immune Response to 2009 H1N1 Influenza Vaccine in HIV-Infected Adults: A Randomized Clinical Trial. Oxford Journals. J Infect Dis. (2012) nº 205 (5), páginas 703-712. Consulta 6 enero, 2015, de la Wold Wide Web: http://jid.oxfordjournals.org/content/205/5/703.long

Siberry GK. (2012). Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in 2 to 10 Year-Old Human Immunodeficiency Virus-Infected Children. NIH, Pediatr Infect Dis J, nº 31(1), páginas 47–52. Consulta 6 enero, 2015, de la Wold Wide Web: www.ncbi.nlm.nih.gov/pmc/articles/PMC3252429/

Siberry GK. et al. (2010). Phase I/II, Open-Label Trial of Safety and Immunogenicity of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Human Immunodeficiency Virus-Infected Adolescents. NIH, Pediatr Infect Dis J, May 2010, nº 29(5), páginas 391–396. Consulta 6 enero, 2015, de la Wold Wide Web: www.ncbi.nlm.nih.gov/pmc/articles/PMC2868314

Rives MT., Menéndez JJ., Calderón B., De José M., Alvarado F., Ruza FJ. (2008). Fallo de la vacuna antineumocócica conjugada en un niño VIH positivo. A propósito de un caso. Anales de pediatría n º1, páginas 59-62. Consulta 10 enero, 2015, de la Wold Wide Web: http://analesdepediatria.org/es/fallo-vacuna-antineumococica-conjugada-un/articulo/S1695403308702418/

Sogaard Os. Et al. (2010) Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV-Infected Adults with a Toll-Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial. Oxford Journals. Clinical Infectious Diseases, nº51 (1), páginas 50-42. Consulta 10 enero, 2015, de la Wold Wide Web: http://cid.oxfordjournals.org/content/51/1/42.full?sid=ab2e5d45-8896-45f4-aeed-a4e19598ef4c

French N. (2010). A trial of 7-valent Pneumococcal Conjugate Vaccine in HIV-infected Adults. N Engl J Med., nº 362 (9) páginas 822–812. Consulta 10 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873559/

Lu CL. Et al. (2012). Impact of vaccination with seven-valent pneumococcal conjúgate vaccine on virologic and Immunologic outcomes among HIV-infected adult patients in the era of highly active antirretroviral therapy. J Formos Med Assoc., nº 111(8), páginas 445-51. Consulta 11 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pubmed/22939663

Myron JL et al. (2011). Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old. PMC, J Acquir Immune Defic Syndr, 2010 Oct, nº 55(2), páginas 197–20. Consulta 11 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033215/

Sow PS. et al. (2013). Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIVSeronegative African Girls and Young Women. The Journal of Infectious Diseases, páginas 1753–63. Consulta 11 enero, 2015, de la Wold Wide Web: http://jid.oxfordjournals.org/content/207/11/1753.long

Denny L. et al. (2013). Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study. ELSEVIER, Volume 31, Issue 48, páginas 5745–5753. Consulta 11 enero, 2015, de la Wold Wide Web: http://www.sciencedirect.com/science/article/pii/S0264410X13012735

Chitsike I., Van Furth R. (1999). Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe. BMJ, nº 318 (7187), páginas 841–843. Consulta 11 enero, 2015, de la Wold Wide Web:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC27799/

American academy of pediatrics. (1999). Measles Immunization in HIV-Infected Children. Pediatrics, volumen 103, Nº 5, páginas 1057 -1060. Consulta 11 enero, 2015, de la Wold Wide Web: http://pediatrics.aappublications.org/content/103/5/1057.full?sid=7f6fee51-5275-4f06-9060-75a737499edf

Aurpibul L., Puthanakit T., Sirisanthana T., Sirisanthana V. (2007). Response to Measles, Mumps, and Rubella Revaccination in HIV-Infected Children with Immune Recovery after Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2007, nº 45 (5), páginas 637-642. Consulta 11 enero, 2015, de la Wold Wide Web: http://cid.oxfordjournals.org/content/45/5/637.long

Scott P., Moss WJ., Gilani Z., Low N. (2011). Measles Vaccination in HIV-Infected Children: Systematic Review and Meta-Analysis of Safety and Immunogenicity. The Journal of Infectious Diseases, 2011, nº 204 (suppl 1), páginas S164-S178. Consulta 11 enero, 2015, de la Wold Wide Web: http://jid.oxfordjournals.org/content/204/suppl_1/S164.long

Abzug MJ. et al. (2007). Pertussis Booster Vaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy. Pediatrics, Volumen 120 Nº 5, páginas e1190 -e1202. Consulta 10 enero, 2015, de la Wold Wide Web: http://pediatrics.aappublications.org/content/120/5/e1190.full.html

Gershon AA. et al. (2009). A phase i–ii study of live attenuated Varicella-Zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous Varicella. Pediatr Infect Dis J, 2009 Jul nº 28(7), páginas 653–655. Consulta 11 enero, 2015, de la Wold Wide Web: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868313/

Weinberg A, Levin MJ, MacGregor RR (2010), “Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults”, Human Vaccines, 2010 Abr, nº 6:4, página 318-321.

Berkowitz EM. et al. (2014). Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study. J Infect Dis, Consulta 11 enero, 2015, de la Wold Wide Web: http://jid.oxfordjournals.org/content/early/2014/12/01/infdis.jiu606.full

Bartlett JG. (2003). Smallpox Vaccination and Patients with Human Immunodeficiency Virus Infection or Acquired Immunodeficiency Syndrome. Clin Infect Dis, 2003, nº 36 (4), páginas 468-471. Consulta 11 enero, 2015, de la Wold Wide Web: http://cid.oxfordjournals.org/content/36/4/468.full


Texto completo: HTML

Refbacks

  • No hay Refbacks actualmente.


Bookmark and Share


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

 

ene

 

 

A MC Rosell. El que la conoció no pudo evitar enamorarse de ella.

A Lourdes Álvaro y a su maravillosa historia de amor y lucha. Cuánto espacio se puede ocupar con poco movimiento.

 

 

Creative Commons License Todo el contenido de esta revista, excepto donde está identificado, está bajo una Licencia Creative Commons